JPMorgan Names Former NOAA Chief Scientist to Lead Climate Advisory

Published 1 days agoJPM

JPMorgan Names Former NOAA Chief Scientist to Lead Climate Advisory

JPMorgan Chase has announced the appointment of Dr. Sarah Kapnick, who previously served as the Chief Scientist at NOAA, as the Global Head of Climate Advisory for its Commercial and Investment Bank. This new role places Dr. Kapnick at the helm of guiding clients through complex issues related to climate, energy, biodiversity, and sustainability.

Dr. Kapnick's responsibilities will focus on helping JPMorgan's clients navigate opportunities that arise from the transition to a low-carbon economy and assisting them in enhancing their resilience to extreme weather events. According to ESG Dive, her leadership will be a crucial part of the bank's effort to integrate climate science into its advisory services, reflecting a growing demand for sustainable investment strategies in the financial sector.

With her return to JPMorgan, Dr. Kapnick brings extensive experience from her time at NOAA, where she directed the agency's science and technology priorities. The appointment signifies JPMorgan's strategic commitment to incorporating climate expertise into its operations, underscoring the broader industry trend of financial institutions embedding climate considerations into their services. Reuters also reported on this significant hire, highlighting the bank's focus on advancing its climate advisory capabilities.

Share this article

Twitter Facebook LinkedIn

Recent Articles

FDA Approves Moderna's Latest COVID Vaccine for Older Adults and High-Risk Groups

FDA Approves Moderna's Latest COVID Vaccine for Older Adults and High-Risk Groups

10 minutes agoMRNA

The U.S. Food and Drug Administration has given the green light to Moderna's new COVID-19 vaccine, mNEXSPIKE, which is specifically aimed at adults aged 65 and older, as well as individuals between 12 and 64 years old who have at least one underlying health condition. This important development seeks to provide enhanced protection for those most vulnerable to severe impacts of the virus. As reported by Reuters, this latest approval aligns with the FDA's guidelines for dealing with populations particularly at risk. Moderna's mNEXSPIKE vaccine stands out for its lower dosage, approximately one-fifth of the original Spikevax formulation, due to advances in its immune-targeting mechanisms. This revised vaccine design is not only more efficient but also better suited for refrigerator storage, making it easier to distribute and increasing its shelf life. The approval comes on the heels of revealing clinical trial results that showed the vaccine's performance as at least on par with its predecessor, with a noted 13.5% higher efficacy in older adults. Amid a backdrop of decreasing demand for earlier vaccines, the FDA's approval sets the stage for mNEXSPIKE's anticipated release, targeting the 2025-2026 respiratory virus season. Meanwhile, Moderna has paused its flu-COVID combination vaccine application in order to gather additional efficacy data. This cautious approach reflects the company's strategy of ensuring safety and effectiveness in their vaccination offerings, as noted by Axios. Such strategic decisions continue to shape Moderna's response to an evolving health landscape.

Sanofi Acquires Blueprint Medicines in $9.5 Billion Deal

Sanofi Acquires Blueprint Medicines in $9.5 Billion Deal

40 minutes agoSNY

Sanofi, the French pharmaceutical giant, has confirmed its acquisition of U.S.-based Blueprint Medicines Corporation for a substantial sum exceeding $9 billion. The agreement includes a cash payment of $129.00 per share, totaling about $9.1 billion, along with a non-tradable contingent value right (CVR) potentially adding $6 per share upon meeting future milestones, bringing the total possible transaction value to $9.5 billion. Reuters reported on this significant move, underscoring its impact on the healthcare sector. Aimed at bolstering Sanofi's presence in rare immunological diseases, the acquisition allows Sanofi to integrate Blueprint's key approved asset, Ayvakit/Ayvakyt, the sole treatment for advanced and indolent systemic mastocytosis in the U.S. and EU markets. This deal not only enhances Sanofi's position in the market but also grants them access to Blueprint's promising pipeline, including elenestinib and BLU-808, which offer potential applications across various immunological conditions. As highlighted by Sanofi’s CEO, Paul Hudson, this transaction is a strategic fit for the company’s ambition to lead in immunology. Leveraging Blueprint’s established relationships with specialists in allergology, dermatology, and immunology, Sanofi aims to strengthen its foothold in the sector. This transaction, the largest healthcare deal in Europe for 2025, reflects Sanofi's strategic focus on expanding in the immunology domain.

POSCO Expands Green Hydrogen Efforts in Australia

POSCO Expands Green Hydrogen Efforts in Australia

55 minutes agoPKX

POSCO Holdings has taken significant steps to advance its sustainable operations in Australia, focusing on green hydrogen production and eco-friendly steelmaking. A key development is the joint study agreement signed on October 12, 2023, with French energy company Engie. This collaboration initiates a pre-feasibility study for the second phase of green hydrogen production in Western Australia, targeting an annual output of 20,000 to 40,000 tons with commercial production slated for 2028. In addition to this, POSCO Holdings and Shinhan Financial Group have jointly invested US$20 million in the Australian hydrogen startup Hysata. This investment is part of Hysata's historic US$111 million Series B funding round, aimed at developing high-efficiency electrolysers essential for green hydrogen production. Furthermore, POSCO Group has laid out ambitious plans to invest US$40 billion in environmental projects across Australia by 2040, with US$28 billion earmarked for hydrogen manufacturing. POSCO's strategic initiatives underline its commitment to harnessing green hydrogen technology and sustainable steel production to enhance global competitiveness. Through partnerships and significant investments, the company aims to strengthen economic ties with Australia, thereby driving advancements in clean energy and core minerals. Reuters reported that these efforts are critical as POSCO positions itself as a leader in the transition to renewable energy sources.

CME Group Hits New Records in Lithium Futures Trading

CME Group Hits New Records in Lithium Futures Trading

CME Group has marked a new milestone in the battery metals market with record-breaking open interest in its lithium futures. As of July 31, 2024, open interest in Lithium Hydroxide futures reached an unprecedented 26,802 contracts, surpassing the previous high from just a day earlier. Meanwhile, open interest for Lithium Carbonate futures also climbed to a record 1,092 contracts, staying ahead of the prior record set on July 30, 2024. The first six months of 2024 saw trading volumes in Lithium Hydroxide futures exceed the entire volume of 2023, highlighting growing investor interest in this area. Specifically, July 30, 2024, was notable for a record daily trading volume of 1,121 contracts in these futures, according to CME Group's reports. This indicates a surge in market activity and engagement in lithium futures, as the global demand for battery metals continues to rise. In a strategic move to capitalize on this momentum, CME Group announced the upcoming launch of Spodumene CIF China Futures set for October 28, 2024, pending regulatory approval. This addition to their suite of battery metals futures is seen as a step to fortify their standing in the market, as they continue to offer robust risk management solutions in this thriving sector. The Financial Times noted CME Group's expansion efforts as a notable challenge to the London Metal Exchange's position in the battery metals market.